Launch of SARS-CoV-2 Antigen Rapid Tests
Updated : 07:02
Immunodiagnostic Systems Holdings plc.
27 November 2020
Launch of SARS-CoV-2 Antigen Rapid Tests
Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that two SARS-CoV-2 Antigen Rapid Test kits are now available for sale in the UK, European Union and other countries which accept the CE mark as the basis of regulatory approval.
Both tests can be performed by a trained healthcare professional in community locations (e.g. workplaces, schools, doctors' surgeries) without the need for any laboratory equipment. These tests determine the presence of the SARS-CoV-2 nucleocapsid protein antigen using direct nasopharyngeal swab samples, providing a result within 15 minutes.
Both fast and easy to use tests are based on the lateral flow principle: one in a cassette format, one in a test card format. These tests are provided by partners of IDS, and have been assessed by the manufacturers as having the following performance characteristics:
| Specificity | Sensitivity | Time to Result |
Lateral Flow cassette | 99.2% | 96.7% | 15 minutes |
Lateral Flow card | 99.3% | 92.0% | 15 minutes |
IDS now offers a comprehensive portfolio of SARS-CoV-2 antigen and antibody tests for the laboratory as well as for community locations; additional information of our SARS-CoV-2 assay portfolio can be found on the IDS website at www.idsplc.com.
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 6111
Jaap Stuut, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.